Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Other hematologic neoplasm 3Tumor-Agnostic 2Myeloid 2Lymphoid 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 2

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
axatilimab × Tumor-Agnostic × Clear all
NCT06320405 2025-12-29

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

OHSU Knight Cancer Institute

Phase 1/2 Recruiting
38 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03238027 2024-05-17

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Syndax Pharmaceuticals

Phase 1 Completed
45 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡